Cargando…
Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms
Aberrant JAK2 signalling plays a central role in myeloproliferative neoplasms (MPN). JAK2 inhibitors have proven to be clinically efficacious, however, they are not mutation-specific and competent enough to suppress neoplastic clonal haematopoiesis. We hypothesized that, by simultaneously targeting...
Autores principales: | Bartalucci, Niccolò, Tozzi, Lorenzo, Bogani, Costanza, Martinelli, Serena, Rotunno, Giada, Villeval, Jean-Luc, Vannucchi, Alessandro M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4117551/ https://www.ncbi.nlm.nih.gov/pubmed/24237791 http://dx.doi.org/10.1111/jcmm.12162 |
Ejemplares similares
-
mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors Effectively Inhibit Cells of Myeloproliferative Neoplasms
por: Bogani, Costanza, et al.
Publicado: (2013) -
Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A/CIP2A axis
por: Bartalucci, Niccolò, et al.
Publicado: (2017) -
Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives
por: Vannucchi, Alessandro M, et al.
Publicado: (2009) -
JAK2 inhibition has different therapeutic effects according to myeloproliferative neoplasm development in mice
por: Debeurme, Franck, et al.
Publicado: (2015) -
Concomitant
JAK2
mutated myeloproliferative neoplasms and hereditary hemochromatosis
por: Loscocco, Giuseppe G., et al.
Publicado: (2022)